Atorvastatin Pre-Treatment Study In Asian Patients With Acute Coronary Syndrome
Status:
Completed
Trial end date:
2010-04-01
Target enrollment:
Participant gender:
Summary
This present study is specifically designed to examine the efficacy and safety of a high
pre-treatment dose of atorvastatin in Asian patients with NSTE-ACS in China and the Republic
of Korea, by using a treatment paradigm similar to that employed in the ARMYDA-ACS study.
Phase:
Phase 4
Details
Lead Sponsor:
Pfizer Pfizer's Upjohn has merged with Mylan to form Viatris Inc.